Britain on Wednesday approved the Pfizer-BioNTech Covid-19 vaccine on independent advice of its medicines regulator.
The vaccine will be made available across the UK from next week.
“The Government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer-BioNTech’s Covid-19 vaccine for use,” a UK Department of Health and Social Care spokesperson said in a statement.
Experts at the MHRA have concluded that the vaccine has met its strict standards of safety, quality and effectiveness after months of rigorous clinical trials and a thorough analysis of the data.
Care home residents, health and care staff, the elderly and the clinically extremely vulnerable will receive the vaccine on priority basis.
“The Joint Committee on Vaccinations and Immunisations (JCVI) will shortly publish its final advice for the priority groups to receive the vaccine,” the spokesperson said.
447 cases of adverse effect reported,Covid-19 vaccine given to 2,24,301 beneficiaries :Govt.
A total of 2,24,301 beneficiaries have been inoculated with COVID-19 vaccine so far, out of which only 447 adverse events following immunisation (AEFI) were reported, the Union Health Ministry said on day two of the nationwide vaccination drive on Sunday.
Addressing a press briefing, the ministry’s Additional Secretary Manohar Agnani said out of the 447 adverse events following immunisation, only three required hospitalisation.
“Today being Sunday, only six states conducted vaccination drive and in 553 sessions a total of 17,072 beneficiaries were vaccinated,” he said.
The six states where the vaccination drive was carried out on Sunday are Andhra Pradesh, Arunachal Pradesh, Karnataka, Kerala, Manipur and Tamil Nadu, he added.
Agnani said a total of 2,24,301 beneficiaries have been vaccinated till January 17 as per provisional reports, adding that 2,07,229 of them received the jabs on day one of the drive.
“A total of 447 AEFI have been reported on January 16 and 17, out of which only three required hospitalisation. Most of the AEFI reported so far are minor like fever, headache, nausea,” he said.
He said a meeting was held with all states and union territories on Sunday to review the progress of the drive, identify bottlenecks and plan corrective actions.
Prime Minister Narendra Modi rolled out the world’s largest inoculation drive against COVID-19 on Saturday and said the two vaccines being deployed will ensure a “decisive victory” for India against the pandemic.
India has approved two vaccines—Covaxin developed by Bharat Biotech and Covishield from the Oxford/AstraZeneca stable being manufactured by the Serum Institute of India—for emergency use in the country.
According to the government, the shots will be offered first to an estimated one crore healthcare workers and around two coror frontline workers, and then to persons above 50 years of age, followed by persons younger than 50 years of age with associated comorbidities. PTI